Moreover, lazertinib has also shown excellent blood–brain barrier (BBB) permeability and intracranial efficacy in EGFR‐mutated brain metastasis model [15], indicating its potential effectiveness for EGFR‐mutated NSCLC patients with brain metastasis. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.